非小细胞肺癌免疫治疗疗效预测新指标——LIPI评分系统

doi:10.3760/cma.j.cn371439-20190926-00023

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (5): 301-303.doi: 10.3760/cma.j.cn371439-20190926-00023

非小细胞肺癌免疫治疗疗效预测新指标——LIPI评分系统

张爱霞(), 孙亚红

山东第一医科大学第三附属医院(山东省医学科学院附属医院)肿瘤内二科,济南 250031

收稿日期:2019-09-26 修回日期:2020-01-20 出版日期:2020-05-08 发布日期:2020-07-02
通讯作者: 张爱霞 E-mail:doctorzhangax@163.com
基金资助:
山东省医学科学院医药卫生科技创新工程

A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)

Zhang Aixia(), Sun Yahong

Second Department of Oncology, Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan 250031, China

Received:2019-09-26 Revised:2020-01-20 Online:2020-05-08 Published:2020-07-02
Contact: Zhang Aixia E-mail:doctorzhangax@163.com
Supported by:
Innovation Project of Shandong Academy of Medical Sciences

摘要/Abstract

摘要：

免疫检查点抑制剂已被证实可显著提高多种恶性肿瘤患者的生存率,因此需要寻找有效的疗效预测指标来指导免疫治疗。肺免疫预后指数(LIPI)是近期发展起来的预测非小细胞肺癌免疫治疗疗效的新指标。基线LIPI能够识别免疫治疗潜在获益人群,是一种方便有效的预后预测指标。

关键词: 癌,非小细胞肺, 预后, 免疫检查点抑制剂, 肺免疫预后指数

Abstract:

Immune checkpoint inhibitors have demonstrated the ability to significantly improve survival across a range of cancers. So predictive markers are required to guide treatment decisions. The lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. The pre-treatment LIPI is a convenient prognostic marker able to idenjpgy ICIs-treated patient groups with significantly different survival and response outcomes.

Key words: Carcinoma,non-small-cell lung, Prognosis, Immune checkpoint inhibitor, Lung immune prognostic index

张爱霞, 孙亚红. 非小细胞肺癌免疫治疗疗效预测新指标——LIPI评分系统[J]. 国际肿瘤学杂志, 2020, 47(5): 301-303.

Zhang Aixia, Sun Yahong. A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)[J]. Journal of International Oncology, 2020, 47(5): 301-303.

参考文献 20

[1]	Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018,359(6382):1350-1355. DOI: 10.1126/science.aar4060. doi: 10.1126/science.aar4060 pmid: 29567705
[2]	Park YJ, Kuen DS, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance[J]. Exp Mol Med, 2018,50(8):109. DOI: 10.1038/s12276-018-0130-1. doi: 10.1038/s12276-018-0130-1 pmid: 30135516
[3]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015,373(17):1627-1639. DOI: 10.1056/NEJMoa1507643. doi: 10.1056/NEJMoa1507643 pmid: 26412456
[4]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015,373(2):123-135. DOI: 10.1056/NEJMoa1504627. doi: 10.1056/NEJMoa1504627 pmid: 26028407
[5]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial[J]. Lancet, 2016,387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. doi: 10.1016/S0140-6736(15)01281-7 pmid: 26712084
[6]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016,375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi: 10.1056/NEJMoa1606774 pmid: 27718847
[7]	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicenter randomised controlled trial[J]. Lancet, 2017,389(10066):255-265. DOI: 10.1016/S0140-6736(16)32517-X. doi: 10.1016/S0140-6736(16)32517-X pmid: 27979383
[8]	Hopkins AM, Rowland A, Kichenadasse G, et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers[J]. Br J Cancer, 2017,117(7):913-920. DOI: 10.1038/bjc.2017.274. doi: 10.1038/bjc.2017.274 pmid: 28950287
[9]	Prelaj A, Tay R, Ferrara R, et al. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer[J]. Eur J Cancer, 2019,106:144-159. DOI: 10.1016/j.ejca.2018.11.002. doi: 10.1016/j.ejca.2018.11.002 pmid: 30528799
[10]	Peters S, Gettinger S, Johnson ML, et al. Phase Ⅱ trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)[J]. J Clin Oncol, 2017,35(24):2781-2789. DOI: 10.1200/JCO.2016.71.9476. doi: 10.1200/JCO.2016.71.9476 pmid: 28609226
[11]	Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase Ⅱ open-label study of atezolizumab in PD-L1-selected patients with NSCLC[J]. J Thorac Oncol, 2018,13(11):1733-1742. DOI: 10.1016/j.jtho.2018.05.004. doi: 10.1016/j.jtho.2018.05.004 pmid: 29775807
[12]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011,144(5):646-674. DOI: 10.1016/j.cell.2011.02.013. doi: 10.1016/j.cell.2011.02.013
[13]	Zhu L, Li X, Shen Y, et al. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer[J]. Onco Targets Ther, 2016,9:4879-4886. DOI: 10.2147/OTT.S107279. doi: 10.2147/OTT.S107279 pmid: 27540301
[14]	Laird BJ, Fallon M, Hjermstad MJ, et al. Qualityof life in patients with advanced cancer: differential association with performance status and systemic inflammatory response[J]. J Clin Oncol, 2016,34(23):2769-2775. DOI: 10.1200/JCO.2015.65.7742. doi: 10.1200/JCO.2015.65.7742 pmid: 27354484
[15]	McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer[J]. Cancer Treat Rev, 2013,39(5):534-540. DOI: 10.1016/j.ctrv.2012.08.003. doi: 10.1016/j.ctrv.2012.08.003 pmid: 22995477
[16]	Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer[J]. JAMA Oncol, 2018,4(3):351-357. DOI: 10.1001/jamaoncol.2017.4771. doi: 10.1001/jamaoncol.2017.4771 pmid: 29327044
[17]	Sorich MJ, Rowland A, Karapetis CS, et al. Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials[J]. J Thorac Oncol, 2019,14(8):1440-1446. DOI: 10.1016/j.jtho.2019.04.006. doi: 10.1016/j.jtho.2019.04.006 pmid: 30999110
[18]	Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016,387(10030):1837-1846. DOI: 10.1016/S0140-6736(16)00587-0. doi: 10.1016/S0140-6736(16)00587-0 pmid: 26970723
[19]	Kazandjian D, Gong Y, Keegan P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small-cell lung cancer[J]. JAMA Oncol, 2019,5(10):1481-1485. DOI: 10.1001/jamaoncol.2019.1747. doi: 10.1001/jamaoncol.2019.1747
[20]	Kim YJ, Kim CH, Lee SH, et al. Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced NSCLC treated with immune checkpoint inhibitor[J]. J Thorac Oncol, 2019,14(9):1608-1618. DOI: 10.1016/j.jtho.2019.05.033. doi: 10.1016/j.jtho.2019.05.033 pmid: 31195179

非小细胞肺癌免疫治疗疗效预测新指标——LIPI评分系统

A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 20

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[6]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[7]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[10]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[11]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[12]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[13]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[14]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[15]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.